149 related articles for article (PubMed ID: 35020840)
1. Patients diagnosed with COVID-19 and treated with anakinra: a real-world study in the USA.
Rich C; Eriksson D; Dolfi F; Jablonska K; Dabbous F; Nazir J
Clin Exp Immunol; 2022 Apr; 207(2):218-226. PubMed ID: 35020840
[TBL] [Abstract][Full Text] [Related]
2. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial.
CORIMUNO-19 Collaborative group
Lancet Respir Med; 2021 Mar; 9(3):295-304. PubMed ID: 33493450
[TBL] [Abstract][Full Text] [Related]
3. Characteristics and clinical outcome in 312 patients with moderate to severe pneumonia due to SARS-COV-2 and hyperinflammation treated with anakinra and corticosteroids: A retrospective cohort study.
Aomar-Millán IF; de Victoria-Carazo JM; Fernández Reyes D; Torres-Parejo Ú; Pérez Fernández L; Martínez-Diz S; Ceballos Torres A; López Gómez J; Bizzarri F; Raya Álvarez E; Salvatierra J
PLoS One; 2023; 18(3):e0283529. PubMed ID: 36961847
[TBL] [Abstract][Full Text] [Related]
4. Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammation. A retrospective cohort study.
Aomar-Millán IF; Salvatierra J; Torres-Parejo Ú; Faro-Miguez N; Callejas-Rubio JL; Ceballos-Torres Á; Cruces-Moreno MT; Gómez-Jiménez FJ; Hernández-Quero J; Anguita-Santos F
Intern Emerg Med; 2021 Jun; 16(4):843-852. PubMed ID: 33400157
[TBL] [Abstract][Full Text] [Related]
5. Comparison of anakinra and tocilizumab in management of severe COVID-19: a retrospective cohort study.
Küçükşahin O; Erden A; Karakaş Ö; Güven SC; Armağan B; Şahiner EŞ; İnan O; Kurtipek AC; Gemcioğlu E; Karaahmetoğlu S; Turan S; İzdeş S; Erdem D; Aypak A; Ayhan M; Akıncı E; Bodur H; Güner R; Omma A; Ateş İ
Turk J Med Sci; 2022 Oct; 52(5):1486-1494. PubMed ID: 36422492
[TBL] [Abstract][Full Text] [Related]
6. Use of Anakinra to Prevent Mechanical Ventilation in Severe COVID-19: A Case Series.
Navarro-Millán I; Sattui SE; Lakhanpal A; Zisa D; Siegel CH; Crow MK
Arthritis Rheumatol; 2020 Dec; 72(12):1990-1997. PubMed ID: 32602262
[TBL] [Abstract][Full Text] [Related]
7. Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study.
Bozzi G; Mangioni D; Minoia F; Aliberti S; Grasselli G; Barbetta L; Castelli V; Palomba E; Alagna L; Lombardi A; Ungaro R; Agostoni C; Baldini M; Blasi F; Cesari M; Costantino G; Fracanzani AL; Montano N; Monzani V; Pesenti A; Peyvandi F; Sottocorno M; Muscatello A; Filocamo G; Gori A; Bandera A
J Allergy Clin Immunol; 2021 Feb; 147(2):561-566.e4. PubMed ID: 33220354
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study.
Cavalli G; De Luca G; Campochiaro C; Della-Torre E; Ripa M; Canetti D; Oltolini C; Castiglioni B; Tassan Din C; Boffini N; Tomelleri A; Farina N; Ruggeri A; Rovere-Querini P; Di Lucca G; Martinenghi S; Scotti R; Tresoldi M; Ciceri F; Landoni G; Zangrillo A; Scarpellini P; Dagna L
Lancet Rheumatol; 2020 Jun; 2(6):e325-e331. PubMed ID: 32501454
[TBL] [Abstract][Full Text] [Related]
9. Tocilizumab versus anakinra in COVID-19: results from propensity score matching.
Arcani R; Correard F; Suchon P; Kaplanski G; Jean R; Cauchois R; Leprince M; Arcani V; Seguier J; De Sainte Marie B; Andre B; Koubi M; Rossi P; Gayet S; Gobin N; Garrido V; Weiland J; Jouve E; Couderc AL; Villani P; Daumas A
Front Immunol; 2023; 14():1185716. PubMed ID: 37304271
[TBL] [Abstract][Full Text] [Related]
10. Anakinra treatment in critically ill COVID-19 patients: a prospective cohort study.
Kooistra EJ; Waalders NJB; Grondman I; Janssen NAF; de Nooijer AH; Netea MG; van de Veerdonk FL; Ewalds E; van der Hoeven JG; Kox M; Pickkers P;
Crit Care; 2020 Dec; 24(1):688. PubMed ID: 33302991
[TBL] [Abstract][Full Text] [Related]
11. Glucocorticoids with low-dose anti-IL1 anakinra rescue in severe non-ICU COVID-19 infection: A cohort study.
Borie R; Savale L; Dossier A; Ghosn J; Taillé C; Visseaux B; Jebreen K; Diallo A; Tesmoingt C; Morer L; Goletto T; Faucher N; Hajouji L; Neukirch C; Phillips M; Stelianides S; Bouadma L; Brosseau S; Ottaviani S; Pluvy J; Le Pluart D; Debray MP; Raynaud-Simon A; Descamps D; Khalil A; Timsit JF; Lescure FX; Descamps V; Papo T; Humbert M; Crestani B; Dieude P; Vicaut E; Zalcman G;
PLoS One; 2020; 15(12):e0243961. PubMed ID: 33326457
[TBL] [Abstract][Full Text] [Related]
12. High-dose intravenous anakinra treatment is safe and effective in severe and critical COVID-19 patients: a propensity score-matched study in a single center.
Bektaş M; Yüce S; Ay M; Uyar MH; Önder ME; Kılıç Mİ
Inflammopharmacology; 2023 Apr; 31(2):787-797. PubMed ID: 36707494
[TBL] [Abstract][Full Text] [Related]
13. A meta analysis on the utility of Anakinra in severe COVID-19 disease.
Mohamed Hussein AAR; Sayad R; Abdelshafi A; Hammam IA; Kedwany AM; Elkholy SA; Ibrahim IH
Cytokine; 2023 Sep; 169():156311. PubMed ID: 37536222
[TBL] [Abstract][Full Text] [Related]
14. Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: Results of a prospective, open-label, interventional study.
Balkhair A; Al-Zakwani I; Al Busaidi M; Al-Khirbash A; Al Mubaihsi S; BaTaher H; Al Aghbari J; Al Busaidi I; Al Kindi M; Baawain S; Al Alawi A; Al Lawati A; Al Rawahi B; Al-Baimani K; Al Zidi K; Elfatih N; Dawud B; John B; Rehman F; Yousif F; Al Khadouri G; Saber I; Lal J; Gargouri M; Al-Ward M; AbuDraz N; Al Ruqeishi S; Kumar S; Abdelmottaleb W; Al-Naamani Z; Bin Nazar Z; Balkhair O
Int J Infect Dis; 2021 Feb; 103():288-296. PubMed ID: 33217576
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of early anti-inflammatory treatment with high doses of intravenous anakinra with or without glucocorticoids in patients with severe COVID-19 pneumonia.
Pontali E; Volpi S; Signori A; Antonucci G; Castellaneta M; Buzzi D; Montale A; Bustaffa M; Angelelli A; Caorsi R; Giambruno E; Bobbio N; Feasi M; Gueli I; Tricerri F; Calautti F; Castagnola E; Moscatelli A; Rollandi GA; Ravelli A; Cassola G; Sormani MP; Gattorno M
J Allergy Clin Immunol; 2021 Apr; 147(4):1217-1225. PubMed ID: 33556464
[TBL] [Abstract][Full Text] [Related]
16. Anakinra for severe forms of COVID-19: a cohort study.
Huet T; Beaussier H; Voisin O; Jouveshomme S; Dauriat G; Lazareth I; Sacco E; Naccache JM; Bézie Y; Laplanche S; Le Berre A; Le Pavec J; Salmeron S; Emmerich J; Mourad JJ; Chatellier G; Hayem G
Lancet Rheumatol; 2020 Jul; 2(7):e393-e400. PubMed ID: 32835245
[TBL] [Abstract][Full Text] [Related]
17. Intravenous high-dose anakinra drops venous thrombosis and acute coronary syndrome in severe and critical COVID-19 patients: a propensity score matched study.
Çakmak R; Yüce S; Ay M; Uyar MH; Kılıç Mİ; Bektaş M
Sci Rep; 2024 May; 14(1):12369. PubMed ID: 38811592
[TBL] [Abstract][Full Text] [Related]
18. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
[TBL] [Abstract][Full Text] [Related]
19. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.
Valk SJ; Piechotta V; Chai KL; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
Cochrane Database Syst Rev; 2020 May; 5(5):CD013600. PubMed ID: 32406927
[TBL] [Abstract][Full Text] [Related]
20. An open label trial of anakinra to prevent respiratory failure in COVID-19.
Kyriazopoulou E; Panagopoulos P; Metallidis S; Dalekos GN; Poulakou G; Gatselis N; Karakike E; Saridaki M; Loli G; Stefos A; Prasianaki D; Georgiadou S; Tsachouridou O; Petrakis V; Tsiakos K; Kosmidou M; Lygoura V; Dareioti M; Milionis H; Papanikolaou IC; Akinosoglou K; Myrodia DM; Gravvani A; Stamou A; Gkavogianni T; Katrini K; Marantos T; Trontzas IP; Syrigos K; Chatzis L; Chatzis S; Vechlidis N; Avgoustou C; Chalvatzis S; Kyprianou M; van der Meer JW; Eugen-Olsen J; Netea MG; Giamarellos-Bourboulis EJ
Elife; 2021 Mar; 10():. PubMed ID: 33682678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
